Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database
- 10 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (3) , 1243-1251
Abstract
Objective: PsA is a chronic inflammatory arthritis with heterogeneous disease manifestations. Data on the prevalence of PsA in adults differ widely depending on the study and the country. This study aimed to estimate the prevalence and incidence of PsA in France, characterize comorbidities associated to PsA and identify prescribed treatments.Methods: This nationwide cohort study involved the administrative healthcare database (Système National des Données de Santé) of the French health insurance scheme linked to the national hospital discharge database. All adults with PsA registered in the database and identified with a specific International Classification of Diseases, 10th revision code (M07) were included between 1 January 2015 and 31 December 2018.Results: A total of 63 598 patients were identified as having PsA [55.9 years (s.d. 14.4), 45.6% males]. The prevalence of PsA was estimated at 0.1% and the incidence at 8.4 per 100 000 person-years in the general population. The most common comorbidities were hypertension, diabetes, chronic obstructive pulmonary disease and dyslipidaemia. The prevalence of treatment with conventional synthetic DMARDs (csDMARDs), biological or biosimilar DMARDs (b/bsDMARDs) and apremilast for PsA was 25.9% (16 453), 30.4% (19 325) and 3.5% (2231), respectively. Overall, 8966 (14.1%) patients were new users of csDMARDs, 8311 (13.1%) were new users of b/bsDMARDs and 1529 (7.4%) were new users of apremilast. The most common first-line csDMARD was methotrexate (70.9%) and the most frequent first-line b/bsDMARD was adalimumab (30.8%).Conclusion: Our results lead to a better understanding of PsA. Results were similar to those from other published studies using other data sources, which highlights the reliability of insurance databases for studies.Keywords
Funding Information
- French Society of Rheumatology (2ème Année 2019)
This publication has 20 references indexed in Scilit:
- Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta‐Analysis of Observational StudiesArthritis Care & Research, 2016
- Global Prevalence of Spondyloarthritis: A Systematic Review and Meta‐Regression AnalysisArthritis Care & Research, 2016
- European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnnals of the Rheumatic Diseases, 2016
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic ArthritisArthritis & Rheumatology, 2016
- The Epidemiology of Psoriatic ArthritisRheumatic Disease Clinics of North America, 2015
- Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohortAnnals of the Rheumatic Diseases, 2015
- Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular ManifestationsThe Journal of Rheumatology, 2014
- Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasisArthritis Care & Research, 2011
- Hospitalization admission rates for low-income subjects with full health insurance coverage in FranceEuropean Journal of Public Health, 2010
- Prevalence of spondyloarthropathies in France: 2001Annals of the Rheumatic Diseases, 2005